Leustatin

Leustatin Brand names, Leustatin Analogs

Leustatin Brand Names Mixture

No information avaliable

Leustatin Chemical_Formula

C₁₀H₁₂ClN₅O₃

Leustatin RX_link

http://www.rxlist.com/cgi/generic3/cladribine.htm

Leustatin fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=122

Leustatin msds (material safety sheet)

Leustatin MSDS

Leustatin Synthesis Reference

No information avaliable

Leustatin Molecular Weight

285.687 g/mol

Leustatin Melting Point

215 ^oC

Leustatin H₂O Solubility

No information avaliable

Leustatin State

Solid

Leustatin LogP

1.57

Leustatin Dosage Forms

Solution

Leustatin Indication

For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.

Leustatin Pharmacology

Cladribine is a synthetic antineoplastic agent with immunosuppressive effects. Cladribine is one of a group of chemotherapy drugs known as the anti-metabolites. Anti-metabolites stop cells making and repairing DNA. Cancer cells need to make and repair DNA in order to grow and multiply.

Leustatin Absorption

Oral bioavailability is 34 to 48%.

Leustatin side effects and Toxicity

Symptoms of overdose include irreversible neurologic toxicity (paraparesis/quadriparesis), acute nephrotoxicity, and severe bone marrow suppression resulting in neutropenia, anemia and thrombocytopenia.

Leustatin Patient Information

LEUSTATIN (cladribine) Injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Suppression of bone marrow function should be anticipated. This is usually reversible and appears to be dose dependent. Serious neurological toxicity (including irreversible paraparesis and quadraparesis) has been reported in patients who received LEUSTATIN Injection by continuous infusion at high doses (4 to 9 times the recommended dose for Hairy Cell Leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens. Acute nephrotoxicity has been observed with high doses of LEUSTATIN (4 to 9 times the recommended dose for Hairy Cell Leukemia), especially when given concomitantly with other nephrotoxic agents/ therapies.

Leustatin Organisms Affected

Humans and other mammals